OncoHelix offers precision oncology services through cytokine profiling and genomic profiling to identify specific tumor characteristics. This enables personalized treatment plans that enhance patient outcomes in cancer care.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer treatment decisions are increasingly guided by the unique molecular characteristics of a patient's tumor, but comprehensive genomic and immunologic profiling is not always readily available or accessible. This can limit the ability of oncologists to personalize treatment plans and identify targeted therapies or clinical trials for their patients.
Solution
OncoHelix offers a suite of precision oncology services, specializing in both molecular and immunological profiling to provide comprehensive tumor analysis. Using next-generation sequencing (NGS) and cytokine profiling, OncoHelix identifies specific genomic alterations and immune-related changes within a patient's cancer. This in-depth profiling generates a detailed report for oncologists, providing valuable insights into the tumor's unique characteristics. By determining a cancer's "fingerprint," OncoHelix enables a personalized approach to cancer treatment, helping oncologists to identify approved mutation-matched drug treatments or relevant clinical trials.
Target Audience
OncoHelix serves hospitals, laboratories, pharmaceutical companies, and individual patients, working in close partnership with healthcare professionals.
Features
- Comprehensive genomic profiling using Next Generation Sequencing (NGS) to identify gene alterations and mutations
- Immunological profiling through cytokine panels to assess immune-related changes in the tumor
- OncoHelix-1 CGP analysis, a 324-gene panel powered by the Roche AVENIO tumor tissue CGP kit, matching the content of the FoundationOne CDx panel
- Customisable testing solutions to provide scalable support
- Access to sponsored tests